Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials
Maria Schwaederlé(AstraZeneca (Japan)), Razelle Kurzrock(Medical College of Wisconsin), Melissa Zhao(The University of Texas MD Anderson Cancer Center), Vladimir Lazar(Institut Gustave Roussy), John Mendelsohn(Unknown), Alexander M.M. Eggermont(University Medical Center Utrecht), Richard L. Schilsky(American Society of Clinical Oncology)
Cited by 497
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
|Molecular Cancer Therapeutics|2015|2.3k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k